Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Neurol Neurosurg Psychiatry ; 58(1): 44-50, 1995 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-7823066

RESUMO

Recent studies have shown that most newly diagnosed epileptic patients can be satisfactorily treated with a single antiepileptic drug. We therefore undertook a prospective randomised pragmatic trial of the comparative efficacy and toxicity of four major antiepileptic drugs, utilised as monotherapy in newly diagnosed epileptic patients. Between 1981 and 1987 243 adult patients aged 16 years or over, newly referred to two district general hospitals with a minimum of two previously untreated tonic-clonic or partial with or without secondary generalised seizures were randomly allocated to treatment with phenobarbitone, phenytoin, carbamazepine, or sodium valproate. The protocol was designed to conform with standard clinical practice. Efficacy was assessed by time to first seizure after the start of treatment and time to enter one year remission. The overall outcome with all of the four drugs was good with 27% remaining seizure free and 75% entering one year of remission by three years of follow up. No significant differences between the four drugs were found for either measure of efficacy at one, two, or three years of follow up. The overall incidence of unacceptable side effects, necessitating withdrawal of the randomised drug, was 10%. For the individual drugs phenobarbitone (22%) was more likely to be withdrawn than phenytoin (3%), carbamazepine (11%), and sodium valproate (5%). In patients with newly diagnosed tonic-clonic or partial with or without secondary generalised seizures, the choice of drug will be more influenced by considerations of toxicity and costs.


Assuntos
Epilepsias Parciais/tratamento farmacológico , Epilepsia Generalizada/tratamento farmacológico , Epilepsia Tônico-Clônica/tratamento farmacológico , Fenobarbital/uso terapêutico , Fenitoína/uso terapêutico , Ácido Valproico/uso terapêutico , Adolescente , Adulto , Idoso , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Fenobarbital/administração & dosagem , Fenobarbital/efeitos adversos , Fenitoína/administração & dosagem , Fenitoína/efeitos adversos , Estudos Prospectivos , Ácido Valproico/administração & dosagem , Ácido Valproico/efeitos adversos
2.
Physiol Meas ; 14 Suppl 4A: A99-102, 1993 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-8274994

RESUMO

Interictal epileptiform activity recorded by scalp EEG, foramen ovale electrodes and MEG is discussed. Gross differences in waveform between the electric and magnetic records are discussed in the light of intracranial depth recordings.


Assuntos
Eletroencefalografia/métodos , Epilepsia/diagnóstico , Magnetoencefalografia/métodos , Humanos
4.
Lancet ; 2(8458): 752-3, 1985 Oct 05.
Artigo em Inglês | MEDLINE | ID: mdl-2864487

RESUMO

The prognosis for seizure recurrence was assessed in 133 patients who presented at a median of 1 day after a first-ever tonic-clonic seizure. The cumulative probability of recurrence was 20% by 1 month, 28% by 2 months, 32% by 3 months, 46% by 6 months, 62% by 1 year, and 71% by 3 and 4 years. After a first seizure epilepsy is likely to develop in the majority of patients.


Assuntos
Epilepsias Mioclônicas/diagnóstico , Adolescente , Adulto , Fatores Etários , Idoso , Criança , Pré-Escolar , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Recidiva
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...